Insured medical cannabis sales in Germany significantly increases in the second quarter of 2019

October 23, 2019
germany_cannabis_sales-1200x675.gif

In Germany, the sales of medicinal cannabis was at a steady increase until it boomed in the second quarter of 2019. By comparison to the second quarter of 2018, 74% more medical cannabis was reimbursed by German insurers this year. In May, it had surpassed the 10 million euro mark ever since this framework was implemented in 2017, however it dropped to 9.5 million euro in June.

The types of medicinal cannabis that were sold

This data which is published by the German National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) includes all medical cannabis sold until June 2019. These categories include cannabis preparations such as dronabinol, ground flower and full spectrum extracts, finished pharmaceutical products such as Sativex and Canemes, and unprocessed cannabis flower. The unprocessed flowers and flowers used in preparations represent 55% of the total reimbursed cannabis products during the second quarter. However, more flower was sold using private prescriptions which wasn’t applied to the data. Nevertheless, reimbursement among all categories of products grew.

Source: https://mjbizdaily.com

Logo Can Pharma SVG

CanPharma has a pharmaceutical wholesale permission according to §52a of the German Medicines Act, as well as a license to handle narcotics in the meaning of §3 of the German narcotics legislation. Furthermore, CanPharma has a GDP-certified quality assurance system.

MEMBER OF

footerlogos

OFFICES

CanPharma GmbH
Wiesbadener Str. 29
16515 Oranienburg
Germany

CanPharma Portugal
Rua João Fernandes
Lavrador 1 – Sala 6 2825-
132 Vila Nova de Caparica
Portugal

REPRESENTATIVE OFFICES

Berlin
Neue Kantstraße 18
14057 Berlin
Germany

Barcelona
Gran de Gràcia 15, 1-1
08012 Barcelona
Spain